Novo Nordisk A/S (NYSE:NVO) Downgraded by Deutsche Bank Aktiengesellschaft to “Hold”

Deutsche Bank Aktiengesellschaft cut shares of Novo Nordisk A/S (NYSE:NVO) from a buy rating to a hold rating in a research report sent to investors on Monday morning, Marketbeat reports.

NVO has been the topic of a number of other reports. TD Cowen restated a “buy” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 3rd. Morgan Stanley reissued an “underweight” rating and issued a $42.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, December 3rd. CICC Research began coverage on shares of Novo Nordisk A/S in a research report on Friday, January 9th. They set an “outperform” rating and a $73.50 target price on the stock. Citigroup started coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 27th. They issued a “neutral” rating for the company. Finally, Zacks Research cut shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Monday, February 9th. Seven investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Hold” and a consensus target price of $56.07.

Novo Nordisk A/S Trading Down 16.3%

NYSE NVO opened at $39.68 on Monday. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. The stock has a market capitalization of $177.16 billion, a P/E ratio of 11.43 and a beta of 0.67. Novo Nordisk A/S has a 52-week low of $39.34 and a 52-week high of $93.80. The firm has a 50-day moving average price of $53.56 and a 200 day moving average price of $53.23.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. The company had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. Equities research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Announces Dividend

The firm also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be given a $1.2751 dividend. The ex-dividend date is Monday, March 30th. This represents a dividend yield of 541.0%. Novo Nordisk A/S’s payout ratio is currently 23.63%.

Hedge Funds Weigh In On Novo Nordisk A/S

Hedge funds have recently added to or reduced their stakes in the business. Quotient Wealth Partners LLC grew its position in shares of Novo Nordisk A/S by 2.0% in the fourth quarter. Quotient Wealth Partners LLC now owns 9,091 shares of the company’s stock valued at $463,000 after purchasing an additional 177 shares during the last quarter. Certuity LLC raised its position in shares of Novo Nordisk A/S by 3.6% during the 4th quarter. Certuity LLC now owns 5,052 shares of the company’s stock worth $257,000 after purchasing an additional 177 shares during the last quarter. Beacon Financial Group lifted its stake in Novo Nordisk A/S by 4.3% in the 3rd quarter. Beacon Financial Group now owns 4,307 shares of the company’s stock valued at $239,000 after buying an additional 178 shares in the last quarter. Oakworth Capital Inc. grew its holdings in Novo Nordisk A/S by 41.6% during the 4th quarter. Oakworth Capital Inc. now owns 619 shares of the company’s stock valued at $31,000 after buying an additional 182 shares during the last quarter. Finally, True North Advisors LLC grew its holdings in Novo Nordisk A/S by 3.9% during the 4th quarter. True North Advisors LLC now owns 5,305 shares of the company’s stock valued at $270,000 after buying an additional 199 shares during the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Underlying commercial momentum remains: Novo still reports strong Wegovy/Ozempic-era sales and recent quarterly beats that support cash flow and dividends; that steady franchise cushions the setback. Wegovy Growth Beats Expectations
• Neutral Sentiment: Broader market weakness (tariff news, lower futures) amplified NVO’s move today, so part of the decline reflects market context rather than company‑only news. 5 Things to Know Before the Stock Market Opens
• Negative Sentiment: REDEFINE‑4 trial missed its primary non‑inferiority goal: CagriSema produced less weight loss than Lilly’s tirzepatide, raising concerns about Novo’s ability to defend/expand obesity market share. REDEFINE‑4 Trial Results
• Negative Sentiment: Head‑to‑head efficacy gap quantified in market coverage (example: 20.2% average weight loss for CagriSema vs 23.6% for tirzepatide over 84 weeks), a concrete metric investors view as clinically and commercially meaningful. CagriSema vs Tirzepatide Results
• Negative Sentiment: Analyst reaction and legal risk: at least one major shop downgraded NVO to hold and law firms have opened investor investigations alleging possible misstatements, which can increase short‑term selling and volatility. Analyst Downgrade Fraud Investigation Notice
• Negative Sentiment: Market cap and sentiment impact: coverage notes the stock hit multi‑year lows and investors marked off billions in valuation as the market repriced Novo’s obesity growth prospects. Market Reaction / Valuation Impact

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.